Navigation Links
The IMF says journal editorial documents dramatic increase in survival since the 1980s
Date:9/11/2008

North Hollywood, CA September 11, 2008 - The International Myeloma Foundation (IMF)supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicianstoday said survival outcomes have improved dramatically for patients with multiple myeloma, cancer in the bone marrow that affects blood cell production. Writing in the October 10th edition of the Journal of Clinical Oncology*, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent.

"What has changed is not the research capability, it is the availability of potent new classes of drugs without the side effects typically associated with chemotherapy," says Dr. Durie. "The successful agents in myeloma are multifunctional with a diverse impact on cell function and pathways. This may well be the secret of success."

The editorial explains that drug design was spurred by the discovery that thalidomide, originally developed as a sedative, was effective against myeloma through multiple mechanisms of action. As a result we have potent, targeted drugs such as Revlimid® and Velcade®, with improved outcomes.

"The benefits and comparisons are particularly interesting looking at the results with lenalidomide (Revlimid) plus low-dose dexamethasone (steroid) compared with prior results with interferon and levamisole. There is essentially a doubling of survival at two years, with preliminary evidence that this survival will be maintained for at least three to four years."

Dr. Durie notes these achievements with myeloma are now benefiting a wide range of blood cancers as these drugs are being tested in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other blood cancers. In the editorial he says the next step is to identify new agents with "greater efficacy or lesser toxicities" in this setting of already high response rates.


'/>"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
Weber Shandwick Worldwide
Source:Eurekalert

Related biology news :

1. News tips from the Journal of Neuroscience
2. Tips from the Journals of the American Society for Microbiology
3. Story ideas from the Journal of Lipid Research
4. Highlights from the September 2007 Journal of the American Dietetic Association
5. AGU journal highlights -- Sept. 6, 2007
6. Springer will publish Journal of Coastal Conservation
7. ESA celebrates 100 years of insect science journals
8. Springer and the New York Botanical Garden Press join forces to publish botanical journals
9. 200 journals join in theme issues on poverty and human development
10. New ETH Zurich article published in scientific journal Nature
11. Media highlights in the November issues of Biophysical Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... first brain mirroring wellness product via Kickstarter campaign on June 15th to fund ... already pre-ordered the B2v2, exceeding the original Kickstarter goal by more than 150% ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... DuPont gains exclusive rights to the ERS patent portfolio covering CRISPR-Cas genome editing ... commercialize the foundational intellectual property (IP) of the CRISPR-Cas technology from co-inventor and ...
(Date:6/26/2017)... ... ... Two new members were elected to the University City Science Center’s Board ... J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at Temple ... Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, as ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... of a redesigned, easier-to-navigate website for all six of their healthcare job ... nurses, dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and the ...
Breaking Biology Technology: